Basu 2014a

Methods	Randomised clinical trial
Participants	60 adult participants Sex: not described Mean age: not described Inclusion criteria: chronic hepatitis C and with a psychiatric disorder (n = 60, schizophrenia 20/60 (33.3%)), major depression 15/60 (25%), bipolar disorder 20/60 (33.3%), and prior suicidal attempts with depression 5/60 (8.3%). Exclusion criteria: Renal failure with CrCl < 30, sickle cell, thalassaemic syndromes, haemolytic syndrome, co‐infections (HBV, HIV), or CHF NYHA Stage IV.
Interventions	Experimental group: Group 1: simeprevir 150 mg and RBV 1000 mg daily Group 3: simeprevir 150 mg and vitamin D 5000 mg daily. Control group: placebo and RBV 1000 mg daily Co‐intervention: Sofosbuvir 400 mg
Outcomes	Antiviral effect
Notes	Email was sent to Basu and colleagues on 06 June 2016 for additional information on allocation sequence generation and concealment, blinding, incomplete outcome data, protocol, full publication, study sponsor, death, SAE, SVR but reply not received yet.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	The trial is described as open‐label
Blinding of outcome assessment (detection bias) All outcomes	High risk	The trial is described as open‐label
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	It is unclear how many participants dropped out
Selective reporting (reporting bias)	Unclear risk	No protocol could be found
Vested‐interest bias	Unclear risk	It was unclear how the trial was funded
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias